AUSTIN, TEXAS, USA, April 14, 2026
TOBY, Inc. has received FDA Breakthrough Device Designation for its urine-based Multi-Cancer Early Detection (MCED) test, marking a major milestone in the advancement of non-invasive cancer diagnostics. The designation recognizes the test’s potential to enable early detection of multiple cancers from a single urine sample, addressing a critical unmet need in oncology screening. This regulatory recognition places TOBY at the forefront of next-generation diagnostic innovation, highlighting the growing importance of AI-driven, scalable screening technologies in improving patient outcomes and healthcare accessibility.
Breakthrough Designation Accelerates Clinical Development Path
The FDA Breakthrough Device Designation is granted to technologies that demonstrate the potential to provide more effective diagnosis or treatment of life-threatening diseases, while expediting development, assessment, and regulatory review. TOBY’s MCED platform will benefit from enhanced FDA interaction, prioritized review pathways, and accelerated clinical validation processes, enabling faster progression toward commercialization.
This designation underscores the importance of regulatory frameworks in supporting innovative medical technologies, particularly those capable of transforming disease detection and improving early intervention strategies. The program also reinforces the role of compliance, quality systems, and clinical evidence generation in bringing disruptive diagnostic solutions to market.
Innovative Urine-Based Technology Enables Scalable Screening
Advertisement
TOBY’s MCED test utilizes volatilomics, spectroscopy, and machine learning algorithms to analyze volatile organic compounds (VOCs) in urine, identifying molecular patterns associated with multiple cancer types. Unlike traditional screening methods that often rely on invasive procedures or blood-based biomarkers, this approach offers a simple, non-invasive alternative that can be easily integrated into routine clinical practice.
The ability to detect multiple cancers from a single sample enhances efficiency and supports population-scale screening, addressing limitations of current diagnostic modalities. This innovation reflects a broader shift toward precision diagnostics and AI-enabled healthcare technologies, which aim to improve detection accuracy while reducing patient burden.
Advancing Early Detection in Oncology Care
Early detection remains one of the most critical factors in improving cancer survival rates and treatment outcomes, yet many cancers are diagnosed at advanced stages due to limitations in existing screening methods. TOBY’s platform is designed to detect over ten types of cancer, representing a significant proportion of global cancer incidence. By enabling earlier diagnosis through accessible and scalable testing, the technology has the potential to reduce mortality, improve treatment success rates, and optimize healthcare resource utilization. The Breakthrough Device Designation also builds on the company’s prior recognition for its urine-based bladder cancer test, further validating its innovative approach to non-invasive oncology diagnostics.
Expanding Clinical Validation and Regulatory Strategy
With the designation secured, TOBY plans to advance large-scale clinical studies and evidence generation, supporting future regulatory submissions and reimbursement strategies. The company aims to collaborate closely with regulatory authorities to establish robust clinical validation data, ensuring the test meets the highest standards of safety, accuracy, and reliability.
This phase of development is critical for achieving broad clinical adoption and integration into healthcare systems, particularly as demand for cost-effective and accessible screening solutions continues to grow. The progress also highlights the importance of data-driven validation and regulatory alignment in the successful commercialization of diagnostic technologies.
The FDA Breakthrough Device Designation for TOBY’s urine-based MCED test represents a significant advancement in the field of cancer diagnostics and early detection technologies. By combining innovative scientific approaches, regulatory support, and scalable design, the platform has the potential to transform how cancers are detected and managed globally. As the healthcare industry continues to prioritize early intervention, precision medicine, and patient-centric care, TOBY’s technology exemplifies the future of non-invasive, AI-driven diagnostic solutions in oncology.
Source: TOBY press release
